RDHL - RedHill Biopharma Ltd.
| Previous Close | 7.25 |
| Open | 7.21 |
| Bid | 7.11 x 800 |
| Ask | 8.53 x 900 |
| Day's Range | 7.10 - 7.27 |
| 52 Week Range | 5.13 - 9.57 |
| Volume | 12,970 |
| Avg. Volume | 73,753 |
| Market Cap | 206.349M |
| Beta (3Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals
Israeli pharma could double its Triangle team before FDA approval this year
With FDA approval of its lead drug now just months away, a Israeli pharmaceutical outfit says it could more than double its Raleigh headcount before year-end.
- TheStreet.com
3 Small-Caps That Look Like Bargains at Current Trading Levels
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .
- Motley Fool
3 Biotech Stocks That Could Double Your Money
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
- American City Business Journals
She left one Triangle public company to become CSO of another local public pharma
Just months after exiting a leadership position at another Triangle public company, one career researcher has been tapped as the CSO of another.
- American City Business Journals
Israeli firms ramps up in Raleigh as drug nears approval
On the eve of filing for FDA approval of its lead drug, RedHill executives say the company is already building up its executive team in the Triangle.
- American City Business Journals
RedHill closes $20M public offering to prep commercialization of new drug
RedHill Biopharma just closed on a $20 million public offering to fund the commercial launch of its drug, Talicia – which means expansion of the company's Raleigh team.
- Reuters
RedHill Biopharma's antibiotic succeeds in late-stage study
Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.
- Zacks
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
